AI-Based Clinical Rule Discovery for NMIBC Recurrence through Tsetlin Machines Corresponding authors: Saram Abbas and Kabita Adhikari.
Saram Abbas, Naeem Soomro, Rishad Shafik, Rakesh Heer, Kabita Adhikari · 2025
Read AI-Based Clinical Rule Discovery for NMIBC Recurrence through Tsetlin Machines Corresponding authors: Saram Abbas and Kabita Adhikari. by Saram Abbas, Naeem Soomro, Rishad Shafik, Rakesh Heer, Kabita Adhikari (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2507-19803.txt.
Introduction
Saram Abbas and co-authors build an AI tool to predict bladder cancer return in this 2025 paper. Most bladder cancer cases are non-muscle-invasive, yet up to seventy percent come back after treatment. Old risk tables are dated and weak, most of all for mid-risk cases.
The team used a Tsetlin Machine, a learner that gives clear logic rules a person can read. Trained on the PHOTO trial data with 330 patients, it beat standard tools on F1 score. Its rules point to clear factors like tumor count, surgeon experience, and hospital stay. The authors argue such open logic makes the tool fit for real clinic use.
Catalog record
| CREATOR | Saram Abbas, Naeem Soomro, Rishad Shafik, Rakesh Heer, Kabita Adhikari |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2507-19803
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
AI-Based Clinical Rule Discovery for NMIBC Recurrence through Tsetlin Machines Corresponding authors: Saram Abbas and Kabita Adhikari. Saram Abbas, Naeem Soomro, Rishad Shafik, Rakesh Heer, Kabita Adhikari Abstract Bladder cancer claims one life every 3 minutes worldwide. Most patients are diagnosed with non–muscle–invasive bladder cancer (NMIBC), yet up to 70% recur after treatment, triggering a relentless cycle of surgeries, monitoring, and risk of progression. Clinical tools like the EORTC risk tables are outdated and unreliable—especially for intermediate-risk cases. We propose an interpretable AI model using the Tsetlin Machine (TM), a symbolic learner that outputs transparent, human-readable logic. Tested on the PHOTO trial dataset ( n = 330 n=330 ), TM achieved an F1-score of 0.80, outperforming XGBoost (0.78), Logistic Regression (0.60), and EORTC (0.42). TM reveals the exact clauses behind each prediction, grounded in clinical features like tumour count, surgeon experience, and hospital stay—offering accuracy and full transparency. This makes TM a powerful, trustworthy decision-support tool ready for real-world adoption. I Introduction Bladder cancer is often called the “Cinderella of cancers”—hidden in the shadows and overlooked by policy and research, yet it remains the 5th most common cancer in Europe, claiming over 220,000 lives each year globally and generating more than €5 billion in annual EU healthcare costs [ 1 , 2 ] . Despite this burden, bladder cancer research is chronically underfunded—receiving just £382 per patient in the UK compared to over £561 for prostate cancer [ 3 ] . Most patients are diagnosed with non-muscle-invasive bladder cancer (NMIBC), which constitutes approximately 75-80% of all bladder cancers. NMIBC recurs in up to 70% of patients, trapping them in a relentless cycle of repeat surgeries [ 4 ] , lifelong cystoscopic surveillance, and costly intravesical treatments- [ 5 ] . This cycle exacts a heavy toll on patients’ quality of life, healthcare systems, and national budgets. Currently, clinicians rely on decades-old tools–such as the EORTC and CUETO risk tables–to predict recurrence, but these often misclassify intermediate-risk patients, leading to inappropriate treatment decisions [ 6 ] . This mismatch between risk stratification and outcome highlights an urgent need for better predictive tools that are both accurate and transparent. In this context, interpretable AI offers a promising path to elevate clinical decision-making and patient care in NMIBC. Contemporary machine learning models such as XGBoost and deep neural networks offer improved accuracy on structured clinical datasets, but they are opaque. Their reliance on post-hoc explainability tools like SHAP or LIME is a barrier to trust and adoption in clinical decision-making [ 7 , 8 ] . In contrast, symbolic AI models like the Tsetlin Machine (TM) promise something long sought in clinical prediction: performance and transparency [ 9 ] . TM learns directly from binary tabular data and outputs propositional rules—human-readable clauses—that clinicians can interpret and act upon. Its success in domains such as ECG classification and medical text analysis motivates its exploration here [ 10 , 11 , 12 ] . In this study, we apply the Tsetlin Machine to the PHOTO trial dataset to: 1. Reconstruct known clinical logic (e.g., EORTC/CUETO) in an interpretable rule-based form; 2. Discover novel, data-driven predictors of recurrence; 3. Benchmark TM against Logistic Regression, XGBoost, and EORTC risk tables in terms of both performance and interpretability. In the following sections, we outline the dataset, modelling approach, and benchmarks. We then present results comparing predictive performance and interpretability, followed by a discussion of clinical relevance. II Methods II-A Dataset and Study Design This retrospective modelling study utilised the PHOTO trial dataset, comprising prospectively collected clinical data from 22 NHS centres across the United Kingdom. The initial cohort consisted of 539 patients diagnosed with non–muscle–invasive bladder cancer (NMIBC). Exclusion criteria included prior cystectomy before diagnosis confirmation, missing three-year follow-up, or incomplete peri-operative data. After exclusions, the final analytic sample included 330 patients. The primary endpoint is tumour recurrence within three years of transurethral resection of bladder tumour (TURBT). This study investigates whether the TM could generate interpretable, clause-based models for recurrence prediction and evaluates its performance against both clinical and machine learning baselines. II-B Data Pre-processing and Modelling Pipeline All modelling was implemented in Python using Scikit-learn , PyTsetlinMachine , and Optuna . The dataset was split 80:20 (train:test), stratified to preserve class balance (40% recurrence). A unified pipeline handled all preprocessing, training, and evaluation steps. Feature Transformation: Continuous features (e.g., tumour count, hospital stay, EQ-5D score) were discretised using clinically meaningful cut-offs and encoded via thermometer encoding. Categorical variables (e.g., smoking status, surgeon grade) were one-hot encoded. Binary features were expanded to include both the feature and its negation, producing Boolean input for the Tsetlin Machine. Class Imbalance: Class weights were applied during training to address the recurrence imbalance and ensure fair learning. Pipeline and Optimisation: A ColumnTransformer integrated all preprocessing into a single reproducible pipeline. An Optuna study with 50 TPE trials tuned the number of bins (n_{\text{bins}}) , clauses, voting threshold (T) , specificity (s) , and training epochs. The objective balanced accuracy with model simplicity to favour interpretability. Training and Evaluation: The best pipeline was retrained on the entire training set and evaluated on the held-out test set. Metrics included accuracy, macro-averaged precision, recall, and F1-score. Comparator Models: • Tsetlin Machine: 80 clauses, T=38 , s=4.0 , 100 epochs. • Logistic Regression: L2-regularised, with class weighting. • XGBoost: n_estimators = 50 , max_depth = 5 , learning_rate = 0.1 . • EORTC Risk Tables: Rule-based model implemented using published scoring logic. All models were trained on identical data splits with consistent preprocessing to ensure fair and reproducible comparison. III Results III-A Patient-Level Clause Activation and Rule Inspection Fig. 1: Heatmap of clause activation across individual patients. Each row represents a patient, each column a learned clause. Blue cells indicate activation (i.e., clause fired), while grey and orange bars on the side represent true and predicted recurrence outcomes, respectively. This enables per-patient interpretability by revealing which clauses influenced the model’s decision to predict recurrence or non-recurrence. Figure 1 presents a visual breakdown of how the top 20 clauses contributed to predictions across individual patients. The lower heatmap shows clause activations (blue = fired, grey = not fired), where each row represents a patient and each column a learned clause. The left-hand side compares ground-truth and predicted recurrence outcomes, enabling visual alignment between clause patterns and model decisions. The upper bar chart ranks clauses by their importance—measured by the difference in firing frequency between recurrent and non-recurrent patients—highlighting the most influential rules in recurrence prediction. To illustrate how clause-level reasoning can support clinical interpretation, we present two representative patients. Each patient activated multiple clauses contributing to the final prediction; for clarity, we highlight a subset—two clauses for Patient A and one for Patient B—that exemplify the model’s interpretable logic. Patient A (Recurrence) : This patient activated multiple recurrence-predictive clauses: Clause C149 HospitalStay > 3 days AND TumourNumber > 3 \rightarrow Recurrence Clause C73 EQ5DScore between 0.41--0.49 AND SurgeonGrade \neq Consultant \rightarrow Recurrence These rules suggest a high-risk profile involving extended hospitalisation, high tumour burden, and less experienced surgical care. While a higher number of tumours is an established risk factor for recurrence, the association between extended hospital stay and recurrence is less well-documented. The TM’s identification